Vcare 2022 Annual Review

Jiangsu Vcare Announces Positive Phase II Results for VC005 Topical Gel, a Second-Generation Highly Selective JAK1 Inhibitor, in the Treatment of Mild-to-Moderate Atopic Dermatitis (AD)

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced that the Phase II clinical study of VC005 topical gel, a self-developed second-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD) in adults in China has successfully completed unblinding and preliminary analysis, yielding positive results.

View Details

Jiangsu Vcare’s Next-Generation TRK Inhibitor Eratrectinib (VC004) Selected for the “SPARK Plan” for Pediatric Oncology Drugs

Recently, Eratrectinib (VC004), a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), was included in the " Support Anti-tumor drugR&D for Kids (SPARK Plan)" launched by the CDE of the NMPA, become the 5th innovative drug variety in the country to be included in this program. This important progress will accelerate the R&D process of the domestic new anticancer drug Eratrectinib in the field of pediatric oncology, bringing new hope to pediatric oncology patients in China.

View Details

Jiangsu Vcare Announces First Patient Enrollment in Phase Ⅱ Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor, for Oral Treatment of Vitiligo

Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced the completion of first patient enrollment in the Phase Ⅱ clinical trial of VC005 Tablets. This independently developed next-generation highly selective JAK1 inhibitor is being evaluated for the oral treatment of non-segmental vitiligo (NSV). The trial aims to assess the efficacy, safety, and PK profile of VC005 Tablets in Chinese adult NSV patients, providing a basis for the selection of dosage in subsequent clinical studies.

View Details

Jiangsu Vcare Completes Phase III Enrollment of VC005, a Next-Generation High-Selective JAK1 Inhibitor for Moderate-to-Severe Atopic Dermatitis

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has achieved a major milestone in the Phase Ⅲ clinical trial of VC005 Tablets – the company's independently developed second-generation highly selective JAK1 inhibitor for oral treatment of moderate-to-severe atopic dermatitis (AD) – with the successful completion of full patients enrollment. This multicenter, randomized, double-blind, placebo-controlled pivotal Phase Ⅲ study aims to further validate the efficacy and safety of VC005 Tablets in adult patients with moderate-to-severe AD. The smooth completion of enrollment marks a crucial step forward for this innovative drug towards clinical application.

View Details

Jiangsu Vcare Launches Phase III Clinical Trial of VC005, a Highly Selective JAK1 Inhibitor, for Ankylosing Spondylitis

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the official initiation of the Phase III clinical trial of VC005 Tablets—a self-developed second-generation highly selective JAK1 inhibitor—for the oral treatment of ankylosing spondylitis (AS). This marks the second Phase III clinical trial of VC005 Tablets, following the one for oral treatment of moderate-to-severe atopic dermatitis (AD), signifying that the AS indication has entered the confirmatory clinical research stage.

View Details

Jiangsu Vcare Initiates Phase II Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor, for Oral Treatment of Vitiligo

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) officially initiated the Phase II clinical trial of VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by the company, for a new oral indication – the treatment of non-segmental vitiligo (NSV).

View Details